Paris

• A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF Ended recruitment
  2025-520809-12-00 10 2025-10-16 Diabetic Macular Edema
• Ribociclib in combination with endocrine therapy in patients with “estrogen receptor-positive and HER2-negative” breast cancer with high ris … Ended recruitment
  2023-508827-10-00 4 2025-10-13 Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
• Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC) Ended recruitment
  2025-521681-10-00 4 2025-10-02 Lung Cancer
• Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended recruitment
  2025-521115-40-00 4 2025-09-30 Advanced or Metastatic Non-small Cell Lung Cancer
• Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL … Ended recruitment
  2024-520050-38-00 5 2025-09-18 Extensive stage small cell lung cancer (ES-SCLC). S
• A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease Ended recruitment
  2024-519746-70-01 4 2025-09-15 Sickle Cell Disease
• Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) Ended recruitment
  2024-511452-40-00 10 2025-09-12 Oncology - Glioblastoma (GBM)
• A Study to Find Out How Safe and Effective AZD0780 Is for Adults with High 'Bad' Cholesterol from an Inherited Condition Ended recruitment
  2025-520520-17-00 5 2025-09-05 Heterozygous familial hypercholesterolaemia
• Long-term Extension Study of Ulviprubart (ABC008) in Subjects with Inclusion Body Myositis Ended recruitment
  2024-517623-39-00 5 2025-08-25 inclusion body myositis
• A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen … Ended recruitment
  2024-513572-17-00 5 2025-08-20 Generalized Anxiety Disorder (GAD)
• A clinical study of tulisokibart in people with hidradenitis suppurativa (MK-7240-012) Ended recruitment
  2024-520039-33-00 10 2025-08-11 Hidradenitis Suppurativa
• A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS Ended recruitment
  2023-510479-72-00 3 2025-08-05 Relapsed/Refractory AML or Higher-Risk MDS
• A study to assess the efficacy and safety of Empasiprubart versus IVIg in adults with Multifocal Motor Neuropathy Ended recruitment
  2024-516473-72-00 5 2025-07-31 Multifocal Motor Neuropathy
• A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended recruitment
  2024-519773-19-00 5 2025-07-31 Gastroesophageal Junction Adenocarcinoma
• A Study of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease Ended recruitment
  2024-517143-31-00 4 2025-07-18 Autosomal Dominant Polycystic Kidney Disease
• A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants with PMM2-CDG Ended recruitment
  2024-520109-37-00 4 2025-07-09 PMM2-CDG
• A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Ended recruitment
  2024-518339-12-00 4 2025-07-08 Idiopathic Pulmonary Fibrosis
• A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairT … Ended recruitment
  2023-504909-37-00 9 2025-07-03 Cystic fibrosis
• A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended recruitment
  2024-519417-57-00 5 2025-06-25 Thyroid eye disease
• An open-label safety and tolerability clinical trial of PST-611 in dry age-related macular degeneration. Ended recruitment
  2024-519025-37-00 1 2025-06-19 Dry age-related macular degeneration.
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adu … Ended recruitment
  2024-516767-92-01 1 2025-06-17 Health Participants
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr … Ended recruitment
  2024-511754-41-00 4 2025-05-29 idiopathic pulmonary fibrosis

Showing 1,273–1,296 of 2,286 trials